X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (100511) 100511
Patent (33840) 33840
Publication (7597) 7597
Newspaper Article (4867) 4867
Newsletter (1399) 1399
Book Review (829) 829
Magazine Article (668) 668
Book Chapter (605) 605
Conference Proceeding (439) 439
Trade Publication Article (346) 346
Dissertation (286) 286
Web Resource (147) 147
Book / eBook (118) 118
Government Document (15) 15
Reference (10) 10
Data Set (9) 9
Paper (7) 7
Journal / eJournal (5) 5
Streaming Video (4) 4
Transcript (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45778) 45778
animals (39486) 39486
male (34894) 34894
index medicus (24515) 24515
human necessities (24428) 24428
sports (24048) 24048
games (24031) 24031
amusements (24024) 24024
toys, e.g. tops, dolls, hoops, building blocks (23904) 23904
female (23541) 23541
calcium channel blockers - pharmacology (20515) 20515
rats (18825) 18825
pharmacology & pharmacy (14901) 14901
middle aged (14306) 14306
performing operations (12175) 12175
transporting (12175) 12175
calcium channel blockers - therapeutic use (11735) 11735
aged (11521) 11521
hypertension (10435) 10435
adult (10230) 10230
cardiac & cardiovascular systems (9971) 9971
hoisting (9945) 9945
lifting (9945) 9945
hauling (9944) 9944
capstans (9937) 9937
hoists (9937) 9937
tackles, e.g. pulley blocks (9937) 9937
winches (9937) 9937
hypertension - drug therapy (9331) 9331
heart failure (8778) 8778
beta blockers (8394) 8394
in vitro techniques (7969) 7969
neurosciences (7527) 7527
dose-response relationship, drug (7505) 7505
calcium - metabolism (7467) 7467
blood pressure - drug effects (7314) 7314
mice (6642) 6642
peripheral vascular disease (6152) 6152
treatment outcome (6005) 6005
beta-blockers (5801) 5801
mortality (5784) 5784
rats, sprague-dawley (5719) 5719
time factors (5635) 5635
adrenergic beta-antagonists - therapeutic use (5536) 5536
physiology (5420) 5420
antihypertensive agents - therapeutic use (5403) 5403
calcium channel blockers (5203) 5203
angiotensin-converting enzyme inhibitors - therapeutic use (5196) 5196
drug therapy (5119) 5119
cells, cultured (4973) 4973
risk factors (4947) 4947
research (4923) 4923
potassium channel blockers - pharmacology (4662) 4662
rats, wistar (4655) 4655
patch-clamp techniques (4455) 4455
analysis (4242) 4242
angiotensin ii type 1 receptor blockers - therapeutic use (4202) 4202
nifedipine - pharmacology (4157) 4157
drug therapy, combination (4145) 4145
biochemistry & molecular biology (4046) 4046
medicine, general & internal (3830) 3830
hypertension - physiopathology (3823) 3823
care and treatment (3772) 3772
adrenergic beta blockers (3660) 3660
calcium (3615) 3615
blood pressure (3598) 3598
blood-pressure (3522) 3522
membrane potentials - drug effects (3409) 3409
heart rate - drug effects (3304) 3304
calcium channel blockers - administration & dosage (3297) 3297
verapamil - pharmacology (3228) 3228
nifedipine (3225) 3225
angiotensin ii type 1 receptor blockers - pharmacology (3145) 3145
electrocardiography (3069) 3069
electrophysiology (3064) 3064
health aspects (3032) 3032
cardiology (3014) 3014
calcium channels (3001) 3001
potassium channel blockers (2992) 2992
double-blind method (2934) 2934
therapy (2919) 2919
kinetics (2900) 2900
rabbits (2882) 2882
angiotensin (2857) 2857
expression (2852) 2852
medicine & public health (2846) 2846
disease models, animal (2829) 2829
cells (2808) 2808
aged, 80 and over (2804) 2804
calcium channel blockers - adverse effects (2798) 2798
heating (2796) 2796
lighting (2796) 2796
mechanical engineering (2794) 2794
weapons (2790) 2790
blasting (2789) 2789
neurons - drug effects (2743) 2743
calcium-channel blockers (2725) 2725
urology & nephrology (2695) 2695
heart (2673) 2673
inhibition (2624) 2624
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (106) 106
Online Resources - Online (11) 11
UTL at Downsview - May be requested (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (100588) 100588
German (25158) 25158
French (15617) 15617
Russian (1888) 1888
Japanese (1255) 1255
Danish (1236) 1236
Swedish (782) 782
Chinese (675) 675
Norwegian (554) 554
Spanish (422) 422
Polish (228) 228
Korean (210) 210
Portuguese (184) 184
Italian (160) 160
Czech (137) 137
Ukrainian (125) 125
Hungarian (99) 99
Slovak (68) 68
Dutch (64) 64
Romanian (54) 54
Turkish (53) 53
Finnish (32) 32
Bulgarian (20) 20
Hebrew (19) 19
Serbian (19) 19
Croatian (16) 16
Lithuanian (9) 9
Persian (7) 7
Slovenian (7) 7
Bosnian (5) 5
Arabic (3) 3
Icelandic (2) 2
Belarusian (1) 1
Catalan (1) 1
Greek (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 07/2015, Volume 66, Issue 1, pp. 183 - 189
Conflicting data on the relationship between antihypertensive medications and falls in elderly people may lead to inappropriate undertreatment of hypertension... 
aged | blood flow velocity | angiotensin-converting enzyme inhibitors | antihypertensive agents | calcium channel blockers | POPULATION | METAANALYSIS | INCREASES | RISK | HYPERTENSIVE PATIENTS | AUTOREGULATION | HEMODYNAMICS | PRESSURE | PERIPHERAL VASCULAR DISEASE | PEOPLE | CEREBRAL-BLOOD-FLOW | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Calcium Channel Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Adrenergic beta-Antagonists - pharmacology | Accidental Falls - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adrenergic beta-Antagonists - adverse effects | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Disease Susceptibility | Cerebrovascular Circulation - drug effects | Comorbidity | Diuretics - pharmacology | Accidents, Home - prevention & control | Antihypertensive Agents - therapeutic use | Calcium Channel Blockers - pharmacology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Diabetes Mellitus - epidemiology | Calcium Channel Blockers - administration & dosage | Diuretics - therapeutic use | Aged | Cognition Disorders - epidemiology | Diuretics - adverse effects | Life Sciences | Human health and pathology
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 04/2013, Volume 20, Issue 10, pp. 1241 - 1285
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system.... 
ASIC | TRP | Central nervous system | P2X | KCNQ | NMDA | CNS | Ion channels | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | GATED SODIUM-CHANNELS | SUBTYPE-SELECTIVE AGONIST | D-ASPARTATE RECEPTOR | ion channels | ACID-SENSING ION-CHANNEL-1 | central nervous system | GLYCINE ANTAGONIST GV150526 | TARANTULA TOXIN PSALMOTOXIN-1 | TRAUMATIC BRAIN-INJURY | ISCHEMIC CELL-DEATH | PHARMACOLOGY & PHARMACY | PERIPHERAL NEUROPATHIC PAIN | TRANSGENIC MOUSE MODEL | Ligand-Gated Ion Channels - antagonists & inhibitors | Transient Receptor Potential Channels - antagonists & inhibitors | Calcium Channels - metabolism | Humans | Calcium Channel Blockers - therapeutic use | Potassium Channel Blockers - therapeutic use | Sodium Channel Blockers - pharmacology | Calcium Channel Blockers - pharmacology | Ion Channels - antagonists & inhibitors | Potassium Channels - metabolism | Animals | Ion Channels - metabolism | Sodium Channels - chemistry | Calcium Channels - chemistry | Central Nervous System Diseases - drug therapy | Sodium Channels - metabolism | Calcium Channel Blockers - chemistry | Sodium Channel Blockers - therapeutic use | Potassium Channels - chemistry | Sodium Channel Blockers - chemistry | Transient Receptor Potential Channels - metabolism | Ligand-Gated Ion Channels - metabolism | Potassium Channel Blockers - chemistry | Potassium Channel Blockers - pharmacology
Journal Article
Annual Review of Pharmacology and Toxicology, ISSN 0362-1642, 1/2015, Volume 55, Issue 1, pp. 333 - 352
The four major classes of antihypertensive drugs-diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including... 
angiotensin-converting enzyme inhibitors | β-blockers | angiotensin receptor blockers | calcium channel blockers | diuretics | hypertension | Angiotensin-converting enzyme inhibitors | Hypertension | Diuretics | Calcium channel blockers | Angiotensin receptor blockers | CLINICAL-PHARMACOLOGY | CARDIOVASCULAR EVENTS | HEART-FAILURE | beta-blockers | CONVERTING ENZYME-INHIBITORS | BLOOD-PRESSURE REDUCTION | CANADIAN HYPERTENSION | CALCIUM-CHANNEL BLOCKERS | ANGIOTENSIN-RECEPTOR BLOCKERS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CORONARY-ARTERY-DISEASE | Adrenergic beta-Antagonists - classification | Angiotensin-Converting Enzyme Inhibitors - classification | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Treatment Outcome | Structure-Activity Relationship | Antihypertensive Agents - classification | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - chemistry | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers - classification | Hypertension - complications | Calcium Channel Blockers - classification | Diuretics - therapeutic use | Blood Pressure - drug effects | Molecular Structure | Diuretics - classification | Adrenergic beta-Antagonists - therapeutic use | Index Medicus
Journal Article
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 08/2018, Volume 57, Issue 8, pp. 997 - 1007
Recent studies suggest that the β‐blocker drug carvedilol prevents skin carcinogenesis but the mechanism is unknown. Carvedilol is one of a few β‐blockers... 
alprenolol | biased β‐blocker | carcinogenesis | β‐blocker | JB6 P+ cells | β-blocker | biased β-blocker | SURVIVAL | blocker | ACTIVATION | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BREAST-CANCER | THERAPY | ONCOLOGY | PATHWAY | POPULATION-BASED COHORT | biased -blocker | C-JUN | BETA-BLOCKER USE | JB6 CELLS | Melanoma - metabolism | Humans | Carvedilol - pharmacology | Epidermal Growth Factor - metabolism | Male | Melanoma - pathology | Mice, SCID | Carcinogenesis - metabolism | Carcinogenesis - drug effects | Carcinogenesis - pathology | Adrenergic beta-Antagonists - pharmacology | Animals | Melanoma - prevention & control | Mitogen-Activated Protein Kinase 3 - metabolism | Proto-Oncogene Proteins c-jun - metabolism | HEK293 Cells | Mice, Inbred NOD | Phosphorylation - drug effects | Carvedilol - therapeutic use | Anticarcinogenic Agents - pharmacology | Proteome - metabolism | Adrenergic beta-Antagonists - therapeutic use | Anticarcinogenic Agents - therapeutic use | Mitogen-Activated Protein Kinase 1 - metabolism | Prevention | Epidermal growth factor | Cancer | Translocation | Phosphorylation | Fractionation | Transformation | Elk | Xenotransplantation | Melanoma | Antibodies | Extracellular signal-regulated kinase | Arrestin | Carcinogenesis | Nuclear transport | Anticancer properties | Ribosomal protein S6 kinase | Signaling | Carcinogens | Xenografts | Antitumor activity | Skin | Inhibition | Index Medicus
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | ACTION-POTENTIALS | TORSADES-DE-POINTES | DOFETILIDE | CONTRACTILITY | drug-induced proarrhythmia | PROLONGATION | LONG-QT SYNDROME | VENTRICULAR MYOCYTES | MATURATION | IMPEDANCE | TOXICOLOGY | batch variations | RISK-ASSESSMENT | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects
Journal Article
Journal Article